Prevention of diabetic retinopathy

The Lancet

Volumn 373, Issue 9672, 2009, Pages 1316-1318

  Einarsdóttir, Anna B ^a   Stefánsson, Einar ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBESILATE CALCIUM; DORZOLAMIDE; GLUCOSE; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN;

ARTICLE; BLINDNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

EID: 64349105217     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60750-9     Document Type: Note

References (13)

1. Stefansson E., Bek T., Porta M., Larsen N., Kristinsson J.K., and Agardh E. Screening and prevention of diabetic blindness. Acta Ophthalmol Scand 78 (2000) 374-385
2. Bek T., Lund-Andersen H., Hansen A.B., Johnsen K.B., Sandbæk A., and Lauritzen T. The prevalence of diabetic retinopathy in patients with screen-detected type 2 diabetes in Denmark: the ADDITION study. Acta Ophthalmol (2008) 10.1111/j.1755-3768.2008.01207.x published online Sept 23.
3. Chung S.S., and Chung S.K. Aldose reductase in diabetic microvascular complications. Curr Drug Targets 6 (2005) 475-486
4. PKC-DMES study group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 125 (2007) 318-324
5. Davis M.D., Sheetz M.J., Aiello L.P., et al., for the PKC-DRS2 Study Group. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci 50 (2009) 1-4
6. Zhang J.Z., Xi X., Gao L., and Kern T.S. Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy. Curr Eye Res 32 (2007) 883-889
7. Sjølie A., Klein R., Porta M., et al., for the DIRECT programme study group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372 (2008) 1385-1393
8. Haritoglou C., Gerss J., Sauerland C., et al., for the CALDIRET study group. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 373 (2009) 1364-1371
9. Ribeiro M.L., Seres A.I., Carneiro A.M., et al. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1591-1600
10. Pedersen D.B., Jensen P.K., la Cour M., et al. Carbonic anhydrase inhibition increases retinal oxygen tension and dilates retinal vessels. Graefes Arch Clin Exp Ophthalmol 243 (2005) 163-168
11. Stefansson E., and Meaney R.T. Diabetic retinopathy and carbonic anhydrase inhibitors. Invest Ophthalmol Vis Sci 42 suppl (2001) S804 (abstr 4312).
12. Gao B.B., Clermont A., Rook S., et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13 (2007) 181-188
13. Olafsdottir E., Andersson D.K., and Stefansson E. Visual acuity in a population with regular screening for type 2 diabetes mellitus and eye disease. Acta Ophthalmol Scand 85 (2007) 40-45